Benefits
Dental Health Support
BLIS M18 colonizes the oral cavity and produces bacteriocins active against cariogenic bacteria including Streptococcus mutans. Every trial behind this statement was run in children, and the effect depended on how well the strain colonized. In the 3-month trial of 100 caries-active children, S. mutans counts fell only in the children the strain colonized best, and the trial reported no other differences in oral microorganism counts between groups.
Gum Health (Not Measured in the Cited Trials)
This gum-health statement is uncited. None of the three trials on this page measured gingival or periodontal outcomes. They measured plaque scores, salivary S. mutans counts, a caries-risk model score, and salivary buffering capacity and pH. Any gum benefit is an extrapolation, not a finding.
Plaque Reduction
One trial supports this, and the result is borderline. In 100 caries-active children given M18 for 3 months, plaque scores were lower than with placebo at P=0.05, exactly on the conventional significance threshold. That is a single pediatric result sitting on the edge of significance rather than a demonstrated effect.
Oral Microbiome Balance
Colonization by S. salivarius M18 is the proposed mechanism, but the human data are thin. The 3-month trial in 100 children reported no differences in oral microorganism counts between the M18 and placebo groups apart from lower S. mutans in the subgroup the strain colonized best. Broad reduction of pathogenic bacteria was not observed.
Streptococcus mutans Inhibition
Salivaricin M production is the proposed mechanism. In people, the supporting data are two pediatric trials: salivary S. mutans counts fell in 40 children aged 3 to 6 after seven days of use, and in the best-colonized subgroup of the 3-month trial in 100 children. No cited trial tested whether lower S. mutans counts translate into fewer cavities.
Adjunct to Dental Hygiene
Used in conjunction with regular brushing, flossing, dental visits — enhances rather than replaces traditional dental care.
Mechanism of action
Oral Cavity Colonization
S. salivarius M18 colonizes oral cavity competing with pathogenic bacteria for niches.
Salivaricin M Production
Produces salivaricin M — bacteriocin targeting S. mutans (primary cavity-causing bacteria).
Cariogenic Bacteria Inhibition
Bacteriocin production is proposed to suppress cariogenic species. In the cited trials the only organism-level reduction reported was in salivary S. mutans, and in the 3-month trial that reduction appeared only in the best-colonized subgroup, with no other differences in oral microorganism counts between groups. A specific reduction in S. sobrinus was not reported.
Enzyme Production
This mechanism is uncited: no study cited here measured enzyme activity from this strain. The closest measured markers come from the seven-day trial in 40 children, where salivary buffering capacity rose while salivary pH did not change.
Clinical trials
Three randomized trials, all in children. Burton 2013: double-blind, placebo-controlled, 100 caries-active children, 3 months, BLIS M18 named. Di Pierro 2015: randomized controlled, 76 children at high caries risk, 90 days, with the product labeled Carioblis, a different trade name for the same strain rather than BLIS M18. Salim 2023: randomized, 40 children aged 3 to 6, seven days.
Children only. All three cited trials enrolled children, the youngest aged 3 to 6. No adults were studied, so nothing here shows what BLIS M18 does in an adult mouth.
Burton 2013: plaque scores were lower with M18 at P=0.05, exactly on the conventional significance threshold, and S. mutans counts fell only in the subgroup best colonized by the strain, with no other differences in oral microorganism counts between groups. Di Pierro 2015: the Cariogram improved, which is a caries-risk model score rather than a count of new cavities. Salim 2023: salivary S. mutans counts fell and buffering capacity rose after seven days, while salivary pH did not change. None of the three trials reported counts of new cavities, and none measured any immune outcome.